## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($222.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. 5,829 Shares in AbbVie Inc. $ABBV Bought by Regent Peak Wealth Advisors LLC**
- Source: MarketBeat | 20251227T112723 | Somewhat-Bullish | Relevance: 100%
- Regent Peak Wealth Advisors LLC purchased 5,829 shares of AbbVie Inc. (NYSE:ABBV) valued at approximately $1.35 million in the third quarter. Various other hedge funds also adjusted their positions in the company, with institutional investors and hedge funds collectively owning 70.23% of AbbVie stock. The company recently reported strong Q3 earnings, increased its quarterly dividend to $1.73 per share, and holds a "Moderate Buy" consensus rating from analysts with an average target price of $245.84.

**2. AbbVie Inc. $ABBV Shares Sold by Sapient Capital LLC**
- Source: MarketBeat | 20251229T105817 | Somewhat-Bullish | Relevance: 100%
- Sapient Capital LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 3.7% in Q3, selling 8,543 shares but still retaining 219,951 shares valued at approximately $49.11 million. Despite this sale, AbbVie remains Sapient's 23rd largest holding, comprising 0.8% of their portfolio. The article also notes other institutional investors have significantly increased their holdings in ABBV, and the company recently beat Q3 earnings estimates, issued strong Q4 2025 guidance, and raised its quarterly dividend.

**3. Meyer Handelman Co. Has $39.35 Million Stock Holdings in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251228T112056 | Bullish | Relevance: 100%
- Meyer Handelman Co. increased its stake in AbbVie Inc. by 3.1% during the third quarter, bringing its total holdings to 169,964 shares valued at $39.35 million, representing 1.2% of its portfolio. AbbVie surpassed Q3 earnings and revenue estimates and raised its quarterly dividend, while several other large institutional investors also made significant buys or sales of ABBV shares. The company's stock is trading up 0.1% with a market capitalization of $406.63 billion and analysts have a "Moderate Buy" consensus rating with a target price of $245.84.

**4. Carnegie Investment Counsel Purchases 25,146 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251228T090828 | Bullish | Relevance: 100%
- Carnegie Investment Counsel increased its stake in AbbVie Inc. (NYSE:ABBV) by 22.0%, acquiring an additional 25,146 shares and now holding 139,194 shares valued at $32.23 million. This increase follows several analyst upgrades and price target lifts for AbbVie, contributing to a "Moderate Buy" consensus and a $245.84 target price. The company also reported strong Q3 EPS and raised its quarterly dividend, reflecting positive financial performance and investor confidence.

**5. AbbVie Inc. (NYSE:ABBV) Given Average Recommendation of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251228T070741 | Bullish | Relevance: 100%
- Twenty-four analysts have given AbbVie Inc. (NYSE:ABBV) a consensus "Moderate Buy" rating, with an average 12-month price target of $245.84. Several brokers, including Piper Sandler, Morgan Stanley, and HSBC, have recently increased their price targets for the stock. AbbVie exceeded its last quarter's earnings and revenue estimates and raised its quarterly dividend, though its high payout ratio and PE ratio suggest potential sustainability and valuation concerns.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $269 | $261 | +3% |
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | HSBC | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.41 indicates undervaluation relative to growth. Forward P/E 16.2x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $408.0B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.41 |
| Forward P/E | 16.2 |
| Current P/E | 21.7 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 stable at 0.8% (minimal 5-day change). Below STRENGTH zone by 2.2pp (needs >3.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.67), confirming momentum. RSI neutral at 58. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.82% (CS: 84) | Neutral |
| RSI_14 | 57.6 | Neutral |
| MACD Histogram | 0.67 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.122x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $231.01
- **Stop Loss:** $222.61 (3.6% risk)
- **Target:** $239.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 164
- **Position Value:** $37,885.64
- **Portfolio %:** 37.89%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*